Kenanga Research cautioned that it is also unclear at this stage as to the financial impact of the agreement on Pharmaniaga, as no guidance was given in terms of pricing and margins, and the government will likely want to see the Covid-19 vaccine delivered in the most competitive manner as possible.
PETALING JAYA: Pharmaniaga Bhd
’s agreement with the government to supply 12 million doses of Covid-19 vaccine developed by China’s Sinovac Life Sciences Co Ltd, has been priced in by the market and the group’s earnings forecasts remain unchanged by research analysts.
The one-year agreement shall be effective from January 26,2021.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
